Intervention

LY01008

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 2 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials2

Recruiting0

Common conditions4

Lead sponsors shown2

Clinical trials

2 shown

Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male SubjectsNCT05110118 · 2020-08-04

COMPLETED

A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung CancerNCT03533127 · 2017-11-27

UNKNOWN

Common conditions

Non Small Cell Lung Cancer Metastatic2 Non Small Cell Lung Cancer Recurrent2 Metastatic Colorectal Cancer1 Non Small Cell Lung Cancer1

Leading sponsors

Luye Pharma Group Ltd. 1 Shandong Boan Biotechnology Co., Ltd 1

Trial status mix

COMPLETED1

UNKNOWN1

Phase mix

PHASE11

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.